NCT03993340

Brief Summary

This study is a prospective, open-label, multi-center, registry study, designed to show that rescue stenting is safe and effective for emergency large vessel occlusion (ELVO) patients who have mechanical thrombectomy failure. Participants with ELVO will initially underwent mechanical thrombectomy usig stent retriever, contact aspiration or both. After failure of mechanical thrombectomy, rescue stenting will be performed.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
78

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 19, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 20, 2019

Completed
4 days until next milestone

Study Start

First participant enrolled

June 24, 2019

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 5, 2021

Completed
25 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2021

Completed
Last Updated

September 8, 2021

Status Verified

September 1, 2021

Enrollment Period

2 years

First QC Date

June 19, 2019

Last Update Submit

September 7, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • modified Rankin scale

    The rate of good functional outcome defined by modified Rankin Scale score, 0 - 2

    3 months

Secondary Outcomes (1)

  • Patency of the target artery

    1 day to 28 days

Study Arms (1)

1

Rescue stenting group

Device: Rescue stenting

Interventions

The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, modern endovascular thrombectomy using a stent retriever, contact aspiration thrombectomy, or both are allowed. The number of thrombectomy attempts is at the operator's discretion. After failure of standard thrombectomy procedure, rescue stenting with Solitaire will be done. Additional balloon angioplasty, glycoprotein IIb/IIIa inhibitor (GPI), or thrombolytic infusions are optional and at the operator's discretion. After successful recanalization with rescue stenting, intravenous maintenance of GPI at least for a 12 hours and then changed to oral antiplatelet are recommended.

1

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with emergent large vessel occlusion and who have not achieved successful recanalization (defined by mTICI, 2b or 3) by mechanical thrombectomy using stent retriever or aspiration thrombectomy.

You may qualify if:

  • \. Subjects experiencing acute ischemic stroke due to large vessel occlusion (intracranial internal carotid artery and middle cerebral artery M1 segment)
  • \. Age 19 or greater
  • \. mRS before qualifying stroke, 0 or 1
  • \. Baseline NIHSS score 4 or more
  • \. CT ASPECTS \> 6 or MR ASPECTS \> 5
  • \. Good collateral statues on CT angiogram (collateral grade by Calgary group, 4 or 5) or corresponding to DEFUSE 3 or DAWN trial on perfusion imaging.
  • \. Onset (last-seen-well) time to femoral puncture time \< 24 hours
  • \. Failure of mechanical thrombectomy with stent retriever, contact aspiration or both
  • \. Subjects who received rescue stenting after failure of mechanical thrombectomy
  • \. Anticipated life expectancy of at least 12 months
  • \. Signed informed consent for study enrollment

You may not qualify if:

  • \. Any contraindication to antiplatelet medication
  • \. Multiple simultaneous large vessel occlusions
  • \. Pregnancy
  • \. Severe contrast allergy or absolute contraindication to iodinated contrast agent
  • \. Patient has a severe or fatal combined illness that will prevent improvement of follow-up or will render the procedure unlikely to benefit the patient.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Severance Hospital Stroke Center, Yonsei University College of Medicine

Seoul, Yeonsei-ro Seodaemun-gu, 03722, South Korea

Location

MeSH Terms

Conditions

Ischemic Stroke

Condition Hierarchy (Ancestors)

StrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 19, 2019

First Posted

June 20, 2019

Study Start

June 24, 2019

Primary Completion

July 5, 2021

Study Completion

July 30, 2021

Last Updated

September 8, 2021

Record last verified: 2021-09

Data Sharing

IPD Sharing
Will not share

Locations